Humacyte (HUMA) announced that it plans to file an Investigational New Drug, IND, application with the U.S. Food and Drug Administration, FDA, ...

Plans for filing an IND was agreed with the FDA in a recent meeting – – Positive preclinical results of the small-diameter ATEV were recently presented at The American Hea ...

IPH4502 is a novel and differentiated topoisomerase I inhibitor ADC designed to precisely target Nectin-4, a cell adhesion ...

The FDA has approved the investigational new drug application of 225Ac-SSO110, allowing for the start of a phase 1/2 trial in ...

Sam Slutsky, an analyst from LifeSci Capital, maintained the Buy rating on ArriVent BioPharma, Inc. (AVBP – Research Report). The associated ...

We appreciated the FDA reviewers' alignment with our proposed clinical development program, and their positive feedback on our intended clinical trial design, IND-enabling studies, and drug ...

A couple of University of Nebraska professors have launched a startup company with the goal of bringing to market an ...

This announcement is based on a press release statement from Silo Pharma. With a current ratio of 7.9, the company maintains strong liquidity to fund its development pipeline, though analysts tracked ...

Two Nebraska researchers have launched a startup company aimed at bringing to market an innovative method for delivering therapeutics, gene editing tools, plasmids and more to targeted locations in ...

Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) ...

Michael Benkowitz, President and COO of United Therapeutics Corp (NASDAQ:UTHR), recently executed a series of stock transactions involving the company's common stock. On January 21, Benkowitz sold ...